Search

Search Constraints

You searched for: Author/Creator Derive, Marc

Search Results

3. Increased sTREM-1 plasma concentrations are associated with poor clinical outcomes in patients with COVID-19. Issue 7 (30th July 2021)

4. Plasma and genetic determinants of soluble TREM-1 and major adverse cardiovascular events in a prospective cohort of acute myocardial infarction patients. Results from the FAST-MI 2010 study. (1st December 2021)

5. Sepsis 2016 Paris. (December 2016)

6. Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial. Issue 7 (7th July 2021)

7. A first‐in‐man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM‐1 receptor inhibition. (20th July 2018)

8. TREM-1 Mediates Inflammatory Injury and Cardiac Remodeling Following Myocardial Infarction. Issue 11 (22nd May 2015)

9. Pharmacological inhibition of the triggering receptor expressed on myeloid cells‐1 limits reperfusion injury in a porcine model of myocardial infarction. (June 2015)

10. Persistently Elevated Soluble Triggering Receptor Expressed on Myeloid Cells 1 and Decreased Monocyte Human Leucocyte Antigen DR Expression Are Associated With Nosocomial Infections in Septic Shock Patients. (24th February 2023)